Bracco Imaging has upgraded its Geneva manufacturing facility as the company moves to scale production of its microbubble technology designed to streamline cell‑therapy manufacturing. The Italy‑based pharmaceutical group said the modernization will enable clinical‑grade GMP production of its streptavidin‑conjugated, lipid‑based microbubble platform—a technology positioned as a more efficient alternative to the magnetic beads that have dominated cell‑selection workflows for four decades. Ma...